EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Performance of Elecsys Anti‐ HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection

Mathias Schemmerer, Lisa Sophie Pflüger iD, Tanja Schneider, Jie Lu, Korbinian Kienle, Kristin Maria Meyer-Schlinkmann, Annelies Mühlbacher, Johannes Polz, Harald Schennach, Qing Xie iD, Christian Voitenleitner, Jürgen Wenzel und 1 weitere

Liver International · 2026

DOI: 10.1111/liv.70480 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Mathias Schemmerer und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Consultant Laboratory for HAV and HEV, Institute of Clinical Microbiology and Hygiene, University Medical Center Regensburg, Regensburg, Ger…. Hauptthemen laut MEDLINE: Hepatitis E, Immunoglobulin M, Immunoglobulin G, Hepatitis E virus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Hepatitis E virus (HEV) is the leading cause of acute viral hepatitis. We evaluated the performance of the new automated Elecsys Anti‐HEV IgG and Elecsys Anti‐HEV IgM assays (Roche Diagnostics) in detecting acute, recent and past HEV infection.

Methods

Performance of the Elecsys assays relative to three commercially available CE‐IVD anti‐HEV assays was assessed in a large multinational cohort (six laboratories in Germany, Austria and China). Sensitivity testing included samples from patients with presumed acute (IgM: n = 707; IgG: n = 490) and recovered HEV infection ( n = 156). Specificity testing included samples from asymptomatic blood donors ( n = 5040), routine diagnostic samples ( n = 2427), and pregnant women ( n = 544). An in‐house anti‐HEV IgG neutralisation method was performed to resolve discrepant specificity sample results. Seroconversion sensitivity analysis was performed using nine commercial seroconversion panels ( n = 119 samples).

Results

Relative sensitivity and specificity of the Elecsys assays were > 98.6% (95% CI: 92.2%–100%) and > 98.9% (98.4%–99.2%) for anti‐HEV IgM and > 81.2% (79.3%–83.0%) for anti‐HEV IgG in different cohorts, respectively. After confirming anti‐HEV IgG in 680/696 discrepant samples by a neutralisation method, relative specificity of the Elecsys Anti‐HEV IgG assay was > 99.4% (98.8%–99.7%). Evaluation of commercial seroconversion panels showed good overall agreement between the assays.

Conclusions

The Elecsys Anti‐HEV IgG and IgM assays showed favourable overall performance when compared to three commercially available CE‐IVD marked assays. Neutralisation data indicated higher sensitivity of the Elecsys Anti‐HEV IgG assay than comparator assays in detecting past infections and lower IgG concentrations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis EImmunoglobulin MImmunoglobulin GHepatitis E virusHepatitis AntibodiesHumansSensitivity and SpecificityFemalePregnancyGermanyMaleChinaAustriaAdultSeroconversionMiddle Aged

Stichwörter der Autor:innen

blood donorshepatitis E virushepatitis antibodiesseroconversionviremia

Substanzen

Immunoglobulin MImmunoglobulin GHepatitis Antibodies

Autor:innen und Institutionen

  • National Consultant Laboratory for HAV and HEV, Institute of Clinical Microbiology and Hygiene, University Medical Center Regensburg, Regensburg, Germany.
  • Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Roche Diagnostics GmbH, Penzberg, Germany.
  • Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • MVZ Labor Krone eGbR, Studienzentrum Immunologie, Bad Salzuflen, Germany.
  • Central Institute for Blood Transfusion and Immunology, Tirol Kliniken GmbH, Innsbruck, Austria.

ORCID-Profile: Lisa Sophie Pflüger, Qing Xie, Marc Lütgehetmann

Förderung

  • Roche Diagnostics

Zitieren

APA

Schemmerer, M., Pflüger, L. S., Schneider, T., Lu, J., Kienle, K., Meyer-Schlinkmann, K. M., Mühlbacher, A., Polz, J., Schennach, H., Xie, Q., Voitenleitner, C., Wenzel, J., & Lütgehetmann, M. (2026). Performance of Elecsys Anti‐ HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection. Liver International. https://doi.org/10.1111/liv.70480

Vancouver

Schemmerer M, Pflüger LS, Schneider T, Lu J, Kienle K, Meyer-Schlinkmann KM, et al. Performance of Elecsys Anti‐ HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection. Liver International. 2026. doi:10.1111/liv.70480

BibTeX
@article{Schemmerer2026,
  author = {Schemmerer, Mathias and Pflüger, Lisa Sophie and Schneider, Tanja and Lu, Jie and Kienle, Korbinian and Meyer-Schlinkmann, Kristin Maria and Mühlbacher, Annelies and Polz, Johannes and Schennach, Harald and Xie, Qing and Voitenleitner, Christian and Wenzel, Jürgen and Lütgehetmann, Marc},
  title = {Performance of Elecsys Anti‐ HEV IgG and IgM Assays for the Detection of Acute, Recent or Past Hepatitis E Virus Infection},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70480}
}
Kostenlos starten →